Skip to content

Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia

Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02175264
Acronym
HCD GENE
Enrollment
73
Registered
2014-06-26
Start date
2014-06-30
Completion date
2016-05-31
Last updated
2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Isolated Non Syndromic Left CDH With Postero Lateral Diaphragmatic Defect With Good Perinatal Outcome

Keywords

Isolated non syndromic CDH

Brief summary

In isolated congenital diaphragmatic hernia (CDH), recurrent risk is low suggesting the occurrence of novo mutations (dominant or recessive). Our objective is to test this hypothesis by combining the search for pathogenic genomic alteration and intragenic mutations through whole exome sequencing in a homogenous group of patients.

Detailed description

To elucidate the genetic basis of non syndromic congenital diaphragmatic hernia in a sub group of individuals with similar phenotype: Isolated CDH presenting with postero-lateral-left diaphragmatic defect with good perinatal outcome (n=16) To establish the prevalence of the identified gene(s) in a cohort of identical patients (n=30) Two complementary approaches will be used: * Search for pathogenic genomic alterations using microarrays (\ 2.106 markers (SNP and CNV) in 16 trios (affected child and 2 parents). * Sequencing of the whole exome from patient genomic DNA (n=16) * Selection of unknown or very rare variants according to different criteria: recessive or dominant model, prediction of their pathogenicity, filtered on genes already known in CDH or involved in diaphragmatic development and non annotated CNV or variants of new gene(s) shared by different patients. * Variants will be validated by Sanger sequencing (for intragenic variants) or quantitative PCR (for CNV) on CDH cases and their parents as well as their absence on 100 controls.

Interventions

GENETICBlood sample

Sponsors

URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Months to No maximum
Healthy volunteers
No

Inclusion criteria

* Families with one (or more) non syndromic CDH child * Signed consent form

Exclusion criteria

* Syndromic CDH or associated with a known karyotype anomaly * No signed consent form * Not affiliated to French social security

Design outcomes

Primary

MeasureTime frame
genes responsible for isolated CDHOne year

Secondary

MeasureTime frame
prevalence of new identified genes in a cohort of CDHOne year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026